Who makes [13C]-radiolabeled Idasanutlin?

[13C]-radiolabeled Idasanutlin is developed by Hoffmann-La Roche.

What development phase is [13C]-radiolabeled Idasanutlin in?

[13C]-radiolabeled Idasanutlin is in Phase 1.

Last reviewed 2026-05-14 · How we verify

[13C]-radiolabeled Idasanutlin

Hoffmann-La Roche · Phase 1 active Small molecule

At a glance

Generic name	[13C]-radiolabeled Idasanutlin
Sponsor	Hoffmann-La Roche
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[13C]-radiolabeled Idasanutlin CI brief — competitive landscape report
[13C]-radiolabeled Idasanutlin updates RSS · CI watch RSS
Hoffmann-La Roche portfolio CI